Evaluation of Glucose Tolerance in Radioiodine Treated Thyroid Carcinoma Patient

Evaluation of Glucose Tolerance in Radioiodine Treated Thyroid Carcinoma Patient: A prospective cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20180601003

Enrollment

Registered

2018-06-01

Start date

2018-05-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid carcinoma treated with radioactive iodine radioactive iodine glucose tolerance thyroid carcinoma

Interventions

The Thyroid cancer patient who will undogo treat with high dose (>100 millicurie) radioactive iodine

Screening

Radioactive iodine treated thyroid cancer

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Differentiated thyroid carcinoma patients, age 18-75 years who undergo high dose (>100 mcu) RAI. 2. The person who can follow the protocol

Exclusion criteria

Exclusion criteria: 1. abnormal glucose tolerance test 2. impaired plasma glucose, Diabetes mellitus 3. glucocorticoid used 4. creatinine > 1.5 mg/dl 5. liver disease; ALT > 2.5x Upper normal limit 6. previous treatment with radioactive iodine 7. pregnancy/planned pregnancy

Design outcomes

Primary

Measure	Time frame
insulinogenic index 6 months 75 gm OGTT,insulinogenic index 6 months 75 gm OGTT	—

Secondary

Measure	Time frame
lipid profile 6 months 75 gm OGTT,Insulin sensitivity index 6 months 75 gm OGTT,Disposition index 6 months 75 gm OGTT, HOMA-IR 6 months 75 gm OGTT,body weight and body mass index 6 months 75 gm OGTT	—

Countries

Thailand

Contacts

Public ContactThachanun Porntharukchareon

Division of Endocrinology, Faculty of Medicine, Chulalongkorn University

nun_po@hotmail.com0818305518

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026